Journal of Cell Communication and Signaling

, Volume 5, Issue 2, pp 101–110

Proteasome inhibitors in cancer therapy

  • Lisa J. Crawford
  • Brian Walker
  • Alexandra E. Irvine
Review

DOI: 10.1007/s12079-011-0121-7

Cite this article as:
Crawford, L.J., Walker, B. & Irvine, A.E. J. Cell Commun. Signal. (2011) 5: 101. doi:10.1007/s12079-011-0121-7

Abstract

The ubiquitin proteasome pathway plays a critical role in regulating many processes in the cell which are important for tumour cell growth and survival. Inhibition of proteasome function has emerged as a powerful strategy for anti-cancer therapy. Clinical validation of the proteasome as a therapeutic target was achieved with bortezomib and has prompted the development of a second generation of proteasome inhibitors with improved pharmacological properties. This review summarises the main mechanisms of action of proteasome inhibitors in cancer, the development of proteasome inhibitors as therapeutic agents and the properties and progress of next generation proteasome inhibitors in the clinic.

Keywords

Proteasome inhibitor Therapeutics Cancer 

Copyright information

© The International CCN Society 2011

Authors and Affiliations

  • Lisa J. Crawford
    • 1
  • Brian Walker
    • 2
  • Alexandra E. Irvine
    • 1
  1. 1.Centre for Cancer Research and Cell BiologyQueen’s University BelfastBelfastNorthern Ireland
  2. 2.Department of PharmacyQueen’s University BelfastBelfastNorthern Ireland

Personalised recommendations